Effect of Verapamil on Glycemic Control in Type 2 Diabetic Hypertensive Patients in Saudi Arabia: A Quasi Experimental Study.
Humans
Male
Diabetes Mellitus, Type 2
/ drug therapy
Female
Middle Aged
Verapamil
/ therapeutic use
Saudi Arabia
/ epidemiology
Hypertension
/ drug therapy
Blood Glucose
/ drug effects
Glycated Hemoglobin
/ metabolism
Aged
Antihypertensive Agents
/ therapeutic use
Glycemic Control
/ methods
Insulin Resistance
Blood Pressure
/ drug effects
C-Peptide
/ blood
Adult
Calcium Channel Blockers
/ therapeutic use
Journal
Nigerian journal of clinical practice
ISSN: 1119-3077
Titre abrégé: Niger J Clin Pract
Pays: India
ID NLM: 101150032
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
16
11
2023
accepted:
12
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
30
8
2024
Statut:
ppublish
Résumé
Type 2 diabetes is a common chronic disease that continues to increase in prevalence globally and is a major healthcare burden. Diabetes and hypertension frequently occur concurrently, and the use of antihypertensive agents is common in diabetic patients. One antihypertensive agent, verapamil, has tentatively shown potentially positive effects on glycemic control in assorted pre-clinical models. To evaluate the effect of verapamil on glycemic control in hypertensive type 2 diabetic patients. Type 2 diabetic hypertensive patients were recruited from King Fahad Medical City, Riyadh, KSA, to receive oral verapamil therapy. Blood pressure and glycometabolic parameters, including fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), C-peptide, and homeostatic model assessment insulin resistance (HOMA-IR), were monitored at baseline and after 6 months of verapamil therapy. Thirty-five patients (16 male, 19 female) with a mean age of 57.2 years were recruited. The use of verapamil was associated with non-significant decreases in HbA1c, FPG, C-peptide, and HOMA-IR. However, a sub-group of 17 participants showed a decrease in HbA1c that was ≥0.5%. Univariate logistic regression showed that baseline BMI, HOMA-IR, and C-peptide were significantly (P < 0.05) associated with HbA1c reductions of ≥0.5%. Verapamil is metabolically neutral and allows the stabilization of glycometabolic parameters in type 2 diabetic individuals. Additional research exploring the mechanism behind the variable response to verapamil therapy is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Type 2 diabetes is a common chronic disease that continues to increase in prevalence globally and is a major healthcare burden. Diabetes and hypertension frequently occur concurrently, and the use of antihypertensive agents is common in diabetic patients. One antihypertensive agent, verapamil, has tentatively shown potentially positive effects on glycemic control in assorted pre-clinical models.
AIM
OBJECTIVE
To evaluate the effect of verapamil on glycemic control in hypertensive type 2 diabetic patients.
METHODS
METHODS
Type 2 diabetic hypertensive patients were recruited from King Fahad Medical City, Riyadh, KSA, to receive oral verapamil therapy. Blood pressure and glycometabolic parameters, including fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), C-peptide, and homeostatic model assessment insulin resistance (HOMA-IR), were monitored at baseline and after 6 months of verapamil therapy.
RESULTS
RESULTS
Thirty-five patients (16 male, 19 female) with a mean age of 57.2 years were recruited. The use of verapamil was associated with non-significant decreases in HbA1c, FPG, C-peptide, and HOMA-IR. However, a sub-group of 17 participants showed a decrease in HbA1c that was ≥0.5%. Univariate logistic regression showed that baseline BMI, HOMA-IR, and C-peptide were significantly (P < 0.05) associated with HbA1c reductions of ≥0.5%.
CONCLUSION
CONCLUSIONS
Verapamil is metabolically neutral and allows the stabilization of glycometabolic parameters in type 2 diabetic individuals. Additional research exploring the mechanism behind the variable response to verapamil therapy is warranted.
Identifiants
pubmed: 39212432
doi: 10.4103/njcp.njcp_805_23
pii: 01253091-202427080-00006
doi:
Substances chimiques
Verapamil
CJ0O37KU29
Blood Glucose
0
Glycated Hemoglobin
0
Antihypertensive Agents
0
C-Peptide
0
Calcium Channel Blockers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
965-971Informations de copyright
Copyright © 2024 Copyright: © 2024 Nigerian Journal of Clinical Practice.
Références
Lin J, Thompson TJ, Cheng YJ, Zhuo X, Zhang P, Gregg E, et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metr 2018;16:9.
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271–81.
Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW, et al. Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2020;162:108086.
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311–21.
Alqurashi KA, Aljabri KS, Bokhari SA. Prevalence of diabetes mellitus in a Saudi community. Ann Saudi Med 2011;31:19–23.
Al-Rubeaan K, Al-Manaa H, Khoja T, Ahmad N, Al-Sharqawi A, Siddiqui K, et al. The Saudi Abnormal Glucose Metabolism and Diabetes Impact Study (SAUDI-DM). Ann Saudi Med 2014;34:465–75.
Alwin Robert A, Al Dawish MA. Microvascular complications among patients with diabetes: An emerging health problem in Saudi Arabia. Diab Vasc Dis Res 2019;16:227–35.
Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Yousef M, Sabico SL, et al. Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): A decade of an epidemic. BMC Med 2011;9:76.
Meo SA. Prevalence and future prediction of type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A systematic review of published studies. J Pak Med Assoc 2016;66:722–5.
Mastura I, Chew BH, Lee PY, Cheong AT, Ghazali S, Abdul S. Control and treatment profiles of 70,889 adult type 2 diabetes mellitus patients in Malaysia- A cross-sectional survey in 2009. Int J Collab Res Intern Med Public Health 2011;3:98–113.
Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: A systematic review and meta-analysis. Diabetes Care 2010;33:1859–64.
Xu G, Chen J, Jing G, Shalev A. Preventing β-cell loss and diabetes with calcium channel blockers. Diabetes 2012;61:848–56.
Busch Sørensen M, Sjøstrand H, Sengeløv H, Tiefenthal Thrane M, Juul Holst J, Lyngsøe J. Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus. Eur J Clin Pharmacol 1991;41:401–4.
Khodneva Y, Shalev A, Frank SJ, Carson AP, Safford MM. Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study. Diabetes Res Clin Pract 2016;115:115–21.
Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 2003;16:381–6.
Yin T, Kuo SC, Chang YY, Chen YT, Wang KK. Verapamil use is associated with reduction of newly diagnosed diabetes mellitus. J Clin Endocrinol Metab 2017;102:2604–10.
Carnovale C, Dassano A, Mosini G, Mazhar F, D’Addio F, Pozzi M, et al. The β-cell effect of verapamil-based treatment in patients with type 2 diabetes: A systematic review. Acta Diabetol 2020;57:117–31.
Malayeri A, Zakerkish M, Ramesh F, Galehdari H, Hemmati AA, Angali KA. The effect of verapamil on TXNIP gene expression, GLP1R mRNA, FBS, HbA1c, and lipid profile in T2DM patients receiving metformin and sitagliptin. Diabetes Ther 2021;12:2701–13.
Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, Neuman A. Diagnosis and management of diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med 2016;164:542–52.
Mayet AY. Patient adherence to warfarin therapy and its impact on anticoagulation control. Saudi Pharm J 2016;24:29–34.
Aljabri K, Bokhari S, Aljabri B. Hypertension in Saudi adults with type 2 diabetes. Interventions Obes Diabetes 2018;1:82–6.
Zafari N, Asgari S, Lotfaliany M, Hadaegh A, Azizi F, Hadaegh F. Impact of hypertension versus diabetes on cardiovascular and all-cause mortality in Iranian older adults: Results of 14 years of follow-up. Sci Rep 2017;7:14220.
Fernández R, Puig JG, Rodríguez-Pérez JC, Garrido J, Redon J; TRAVEND Study Group. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: A randomised, double-blind study. J Hum Hypertens 2001;15:849–56.
Rubio-Guerra AF, Arceo-Navarro A, Vargas-Ayala G, Rodriguez-Lopez L, Lozano-Nuevo JJ, Gomez-Harper CT. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care 2004;27:1688–91.
De Geest S, Sabaté E. Adherence to long-term therapies: Evidence for action. Eur J Cardiovasc Nurs 2003;2:323.